EGFR and breast cancer: Together, these findings suggest that CEACAM5 expression and its serum surrogate marker, CEA, may serve as subtype‐specific prognostic or predictive biomarkers in both lung and breast cancers, particularly in tumors driven by EGFR mutations or enriched in luminal and HER2‐related signaling pathways.